ClinicalTrials.gg
RecruitingNCT07474545Updated May 27, 2026

A Study to Evaluate the Safety, Tolerability and Pharmacokinetics of KL0011034 Injection in Healthy Volunteers

A Phase 1 interventional study of KL0011034 injection and Placebo in Healthy Volunteers, sponsored by Hunan Kelun Pharmaceutical Co., Ltd.. Recruiting at 1 site in China. Open to participants aged 18 Years to 45 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-05-27.

Sponsored by Hunan Kelun Pharmaceutical Co., Ltd. (part of Sichuan Kelun Pharmaceutical Co.,Ltd.) · Phase 1, Interventional, and Treatment

From the registry’s dates

  • Started Mar 2026; still recruiting 8 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
76
Allocation
Randomized
Ages
18 Years to 45 Years
Sex
All
01

Study summary

To evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of single intravenous doses of KL0011034 injection in healthy volunteers.

Read the detailed description

This trial is a randomized, double-blind, placebo- and active-controlled, single-dose escalation study in healthy volunteers. A total of 76 volunteers will be enrolled. Healthy volunteers will be randomly assigned to receive KL0011034 injection, placebo, or Etomidate Injectable Emulsion. Each volunteer is allowed to participate in only one dose cohort; intra-volunteer dose escalation is not permitted. Enrollment into the next cohort will begin only after safety and tolerability data from the previous cohort have been reviewed and deemed acceptable by the investigator(s) and sponsor. If the highest dose is well tolerated, the investigator(s) and sponsor will evaluate the accumulated data and decide whether to terminate dose escalation or continue to higher dose levels.

02

Conditions studied

  • Healthy Volunteers

Keywords

  • Healthy
03

In context

Lead sponsor

Hunan Kelun Pharmaceutical Co., Ltd. is the lead sponsor of 9 studies on the registry; 6 are open to participants now.

First submitted after Hunan Kelun Pharmaceutical Co., Ltd. became part of Sichuan Kelun Pharmaceutical Co.,Ltd..

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 45 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Able to understand the purpose, content, procedures, and possible risks of the trial,willing to participate and sign the ;
  2. Volunteers aged 18-45 years (inclusive) at the time of signing the informed consent,no gender limit;
  3. The body weight: Male ≥ 50.0 kg, Female ≥ 45.0 kg; (BMI) within the range of 19.0-26.0 kg/m2 (inclusive);
  4. Agree not to conceive or father a child (and ensure their partners of do not conceive) and agree not to donate gametes from signing informed consent through 3 months after dosing; Agree to use effective during this period;
  5. Able to communicate well with the investigator, and willing to comply with the protocol restrictions, and cooperate with the completion of the trial process.

Exclusion criteria

Exclusion Criteria:

  1. The investigator considers that the volunteer has any current or past medical condition (including but not limited to disorders of the central nervous, cardiovascular, endocrine, respiratory, digestive, urinary, hematological, or lymphatic systems) that may interfere with the trial;
  2. History of anesthesia accident, serious adverse reaction to anesthesia or family history of anesthesia accident prior to screening;
  3. History of difficult mask ventilation, difficult intubation, or anticipated difficult airway management prior to screening, including but not limited to modified Mallampati score III-IV, bifid or absent uvula, micrognathia, or retrognathia;
  4. History of asthma, , or obstructive sleep apnea; or current respiratory disease prior to screening;
  5. History of adrenal insufficiency or adrenal tumor or hereditary heme biosynthesis disorder or hereditary acute porphyria prior to screening;
  6. abnormalities in physical examination, vital signs, chest X-ray, abdominal ultrasound, or clinical laboratory tests; or abnormal circadian rhythm of cortisol or ACTH deemed clinically significant by the investigator;
  7. Clinically significant abnormalities at screening, including ≥ 450 ms (men) or ≥ 460 ms (female);
  8. Seropositive for surface antigen (HBsAg), virus antibody (anti-HCV), antibody (anti-HIV), or Treponema pallidum antibody at screening;
  9. Pregnancy or lactation at screening; or positive pregnancy test for females of ;
  10. Known history of drug or alcohol abuse or dependence within 12 months prior to screening, or positive urine drug test at screening;
  11. Alcohol abuse within 6 months prior to screening, positive breath alcohol test at screening, or unwillingness to abstain from alcohol during the trail;
  12. Positive urine cotinine test at screening, or history of regular smoking (≥5 cigarettes/day) within 6 months prior to screening, or unwillingness to abstain from tobacco use during the trial;
  13. Habitual consumption of >8 cups/day of tea, coffee, or other caffeinated beverages (1 cup ≈ 250 mL) prior to screening, or unwillingness to abstain from the above beverages during the trial;
  14. Use of any medications within the past 14 days, including prescription and over-the-counter medications, traditional Chinese medicine, health care products, and vitamins;
  15. Known allergy to etomidate or other anesthetics;or atopy (defined as allergy to ≥2 medications, foods, or pollen);or prone to developing rashes or hives; or history of allergic diseases;or known allergy to the or active pharmaceutical ingredients;
  16. Participation in any clinical trial within 3 months prior to screening, or failure to complete the follow-up period of a previous trial;
  17. Vaccination within 1 month (inactivated) or 3 months (live) prior to screening, or intent to receive any vaccine dinactivated/live/attenuated vaccine during the trial;
  18. Blood donation, or blood transfusion, or significant blood loss (>400 ml) within 3 months prior to screening; or planned blood donation or surgery during the trail or within 1 month after the trial;
  19. Surgery within 3 months prior to screening, ongoing post-surgical recovery, or planned surgical procedure during the trial;
  20. Difficulty in collecting blood, unable to tolerate venipuncture and/or having a history of haemorrhage or needle halo;
  21. Volunteers with unprotected sexual intercourse within 2 weeks before administration;
  22. Poor compliance,or any other circumstance deemed by the investigator to contraindicate participation.
Terms in these criteria, in plain language(12)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

COPD

Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
76 participants (estimated)

Study arms

  • Experimental
    KL0011034 injection group

    Volunteers will receive KL0011034 injection in different doses.

    Drug: KL0011034 injection

  • Placebo comparator
    KL0011034 injection placebo group

    Volunteers will receive KL0011034 injection placebo.

    Drug: Placebo

  • Active comparator
    Etomidate Injectable Emulsion group

    Volunteers will receive Etomidate Injectable Emulsion.

    Drug: Etomidate Injectable Emulsion

Interventions

  • Intravenous injection, single dose

  • DrugPlacebo

    Intravenous injection, single dose

  • DrugEtomidate Injectable Emulsion

    Intravenous injection, single dose

06

What researchers measure

Primary outcomes

  1. Number of reported Adverse Events

    Safety and tolerability was assessed by the number of volunteers with adverse events.

    Time frame: From first dose of drug until day 2

Secondary outcomes

  1. PK parameter Cmax in plasma

    Maximum peak plasma concentration (Cmax) after single dose.

    Time frame: From first dose of drug until day 2

  2. PK parameter Tmax in plasma

    Time of Cmax (Tmax) after single dose. PK parameters will be assessed for plasma KL0011034 and its metabolite(s) .

    Time frame: From first dose of drug until day 2

  3. PK parameter AUC0-t in plasma

    Area under the concentration-time curve (AUC0-t) from time zero to time "t" after single dose. PK parameters will be assessed for plasma KL0011034 and its metabolite(s) .

    Time frame: From first dose of drug until day 2

  4. PK parameter AUC0-∞ in plasma

    AUC from time zero to infinity (AUC0-∞) after single dose. PK parameters will be assessed for plasma KL0011034 and its metabolite(s) .

    Time frame: From first dose of drug until day 2

  5. PK parameter t1/2 in plasma

    Terminal-phase elimination half-life (t1/2) after single dose. PK parameters will be assessed for plasma KL0011034 and its metabolite(s) .

    Time frame: From first dose of drug until day 2

  6. Modified Observer's Assessment of Alertness Sedation (MOAA/S) scale

    MOAA/S is a commonly used clinical sedation assessment scale, ranging from 0 to 5, which helps clinicians determine the level of sedation in patients. A score of 5 indicates full consciousness, whereas a score of 0 indicates deep coma. Lower scores correspond to deeper levels of sedation.

    Time frame: From first dose of drug until 10 minutes after fully alert on day 1.

  7. Electroencephalogram bispectrality index (BIS) monitoring

    BIS is the most widely used method for the continuous monitoring of sedation depth in clinical anesthesia. BIS values range from 0 to 100, where 100 represents complete wakefulness and 0 indicates complete cortical electrical inhibition.

    Time frame: From first dose of drug until 10 minutes after fully alert on day 1.

  8. Loss of eyelash reflex

    The eyelash reflex is a commonly used clinical method to assess the level of consciousness in patients. Gentle stimulation of the eyelashes with a cotton swab normally elicits a blink; absence of this response indicates loss of the eyelash reflex.

    Time frame: From first dose of drug until the reflex was fully restored on day 1.

  9. Modified Aldrete Scoring (Aldrete) Scale

    The Modified Aldrete Score is the most widely used standardized tool for assessing discharge readiness from post-anesthesia care unit (PACU). It evaluates five parameters: activity, respiration, blood pressure consciousness, and SpO2. Ranging from 0 to 10, the higher the score, the better the quality of recovery.

    Time frame: From being fully alert until meeting the discharge criteria to leave the unit on day 1.

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Mar 2026 (actual). Primary completion is estimated for Dec 2027, 21 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 24, 2026
First posted
Mar 16, 2026
StartActual
Mar 2, 2026
Primary completionEst.
Dec 31, 2027
CompletionEst.
Dec 31, 2027
Last update
May 27, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 27, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07474545
Responsible party
Sponsor
First posted
Mar 16, 2026
Start date
Mar 2, 2026
Primary completion
Dec 31, 2027 (estimated)
Completion
Dec 31, 2027 (estimated)
Last update
May 27, 2026

Study contacts

Wei Qi
Contact
qiw@kelun.com
028-82339360

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: KL0011034

Start the discussion